Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ferriprox™ (deferiprone) is a chelating agent with an affinity for ferric ion (iron III), being developed for the treatment of patients with transfusional iron overload due to thalassemia syndromes.
Product Name : Ferriprox
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2023
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Taro Pharmaceutical Launches Generic Deferiprone in U.S
Details : Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice-a-day tablets
Details : USFDA has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Chiesi Group
Deal Size : Undisclosed
Deal Type : Acquisition
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
Details : Chiesi Group expands distribution network via acquisition for worldwide product rights.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 13, 2020
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Chiesi Group
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2019
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2018
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : The Florey Institute of Neuroscience and Mental Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Deferiprone to Delay Dementia (The 3D Study)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2017
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : The Florey Institute of Neuroscience and Mental Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : SocraMetrics GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2016
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : SocraMetrics GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Parkinson's Early Stage With Deferiprone
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2016
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : European Commission | APOPHARMA
Deal Size : Inapplicable
Deal Type : Inapplicable
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2016
Lead Product(s) : Deferiprone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : European Commission | APOPHARMA
Deal Size : Inapplicable
Deal Type : Inapplicable